Omid Hamid, MD

Articles

Dr Hamid on Addressing Unmet Needs in Relapsed Melanoma With Lifileucel

April 19th 2024

Omid Hamid, MD, discusses how lifileucel may address historical unmet needs in relapsed melanoma.

Dr Hamid on the Use of Lifileucel in Advanced Melanoma

April 16th 2024

Omid Hamid, MD on adoptive T cell therapy, lifileucel, for patients with patients with advanced melanoma.

Dr Hamid on the Rationale For Investigating Fianlimab Plus Cemiplimab in Melanoma

November 23rd 2023

Omid Hamid, MD, director, Melanoma Program, The Angeles Clinic and Research Institute, Cedars-Sinai, discusses the rationale for a phase 1 trial of fianlimab plus cemiplimab in patients with advanced melanoma who have received prior adjuvant PD-1 inhibitors.

Dr. Hamid on the Evolving Treatment of Immunotherapy in Patients With Solid Tumors

October 31st 2022

Omid Hamid, MD, discusses the evolving treatment of immunotherapy in patients with solid tumors.

Future Directions in Metastatic Uveal Melanoma Treatment

August 5th 2022

Omid Hamid, MD, and Ryan Sullivan, MD, discuss what they look forward to in the future of metastatic uveal melanoma treatment.

Managing Tebentafusp Toxicities in Metastatic Uveal Melanoma

July 29th 2022

Experts highlight strategies for managing the adverse events of tebentafusp, especially cytokine release syndrome.

Recent Trial Data on Tebentafusp in Metastatic Uveal Melanoma

July 29th 2022

Dr Ryan Sullivan details clinical trial data presented at ASCO 2022 on the use of tebentafusp for mUM.

Novel Immunotherapy Agent Tebentafusp for Treatment of Metastatic Uveal Melanoma

July 22nd 2022

Dr Omid Hamid explains the mechanism of action of recently approved tebentafusp for mUM, and why HLA testing is necessary for patients being considered for the treatment.

Overview of Metastatic Uveal Melanoma

July 22nd 2022

Ryan Sullivan, MD, provides an overview of metastatic uveal melanoma, currently available treatment options, and unmet needs in the field.

Dr. Hamid on the Differences in Evaluation Criteria for TIL Therapy in Melanoma

January 12th 2022

Omid Hamid, MD, discusses the differences in evaluation criteria for tumor-infiltrating lymphocytes therapy in melanoma.

Dr. Hamid on the Efficacy of TILs Following Immunotherapy in Advanced Melanoma

January 12th 2022

Omid Hamid, MD, discusses the efficacy of tumor-infiltrating lymphocyte therapy following immunotherapy in advanced melanoma.

Dr. Hamid on the Integration of TIL-Based Therapy Into Melanoma

September 30th 2021

Omid Hamid, MD, discusses the integration of tumor infiltrating lymphocyte–based therapy into the melanoma armamentarium.

Dr. Hamid on Promising Triplet Combinations Under Exploration in Melanoma

April 11th 2020

Omid Hamid, MD, discusses promising triplet combination under exploration in melanoma.

Collaboration Saves Lives: Managing irAEs is a "Dynamic Discussion"

January 16th 2020

Omid Hamid, MD, and Grace Cherry, NP, share the importance of multidisciplinary care for patients with melanoma, how to best manage immunotherapy-related adverse events, and tips for developing trusting relationships with patients so that they feel comfortable reporting toxicities.

Dr. Hamid on the FDA Approval of Pembrolizumab in Merkel Cell Carcinoma

December 20th 2018

Omid Hamid, MD, director of Research and Immuno-Oncology at The Angeles Clinic, discusses the FDA approval of pembrolizumab (Keytruda) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma.

Dr. Hamid on the Inclusion of Patients With Brain Metastases on Melanoma Trials

December 1st 2018

Omid Hamid, MD, director of Research and Immuno-Oncology at The Angeles Clinic, discusses the inclusion of patients with brain metastases on melanoma clinical trials.

Dr. Hamid on the Effectiveness of Immunotherapy in AYA Patients With Melanoma

November 3rd 2018

Omid Hamid, MD, director of Research and Immuno-Oncology at The Angeles Clinic, discusses the effectiveness of immunotherapy in adolescent and young adult (AYA) patients with melanoma.

Dr. Hamid on a Retrospective Analysis of Pembrolizumab in Melanoma

October 30th 2018

Omid Hamid, MD, director of Research and Immuno-Oncology at The Angeles Clinic, discusses a retrospective analysis of pembrolizumab (Keytruda) in patients with melanoma.

Dr. Hamid on Epacadostat Plus Pembrolizumab in Advanced Melanoma

September 11th 2017

Omid Hamid, MD, director of the melanoma center at the Angeles Clinic & Research Institute in Los Angeles, discusses the phase III results of the ECHO-202/KEYNOTE-037 trial, which explored the IDO inhibitor epacadostat plus pembrolizumab (Keytruda) in patients with advanced melanoma.

Dr. Hamid on Immunotherapy Approaches in Melanoma

December 22nd 2016

Omid Hamid, MD, chief, Translational Research and Immunotherapy, director, Melanoma Therapeutics, The Angeles Clinic and Research Institute, discusses different immunotherapy approaches that oncologists are currently exploring in melanoma.